

NCT ID	NCT06066424
Title	Phase 1 Dose Escalation and Expansion Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Patients With Advanced Solid Tumors (TROPIKANA)
Phase	Phase 1
Date Added	2023-10-04
Location	Texas, United States
Prior IO Allowed	Yes
CRC-directed	No
Status	Recruiting
Drugs	Cyclophosphamide, Fludarabine Phosphate, Rimiducid, TROP2-CAR-NK Cells
Tags	MSI-H/ MMRd, MSS/ MMRp

NCT ID	NCT06185556
Title	COLDFIRE-III Trial: Efficacy of Irreversible Electroporation and Stereotactic Body Radiotherapy for Perivascular and Peribiliary Colorectal Liver Metastases
Phase	Phase 2
Date Added	2023-12-29
Location	Netherlands
Prior IO Allowed	Yes
CRC-directed	Yes
Status	Recruiting
Drugs	
Tags	MSI-H/ MMRd, MSS/ MMRp

NCT ID	NCT06218914
Title	A Study of NT-112 in HLA-C*08:02-Positive Adult Subjects With Unresectable, Advanced, and/ or Metastatic Solid Tumors Positive for the KRAS G12D Mutation
Phase	Phase 1
Date Added	2024-01-23
Location	California, United States Florida, United States Illinois, United States Kansas, United States Missouri, United States New York, United States Pennsylvania, United States Tennessee, United States Texas, United States Washington, United States Wisconsin, United States
Prior IO Allowed	Yes
CRC-directed	Yes
Status	Recruiting
Drugs	
Tags	MSI-H/ MMRd, MSS/ MMRp

NCT ID	NCT04853017
Title	ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors (AMPLIFY-201)
Phase	Phase 1
Date Added	2021-04-21

Location	California, United States Colorado, United States Iowa, United States Massachusetts, United States Missouri, United States New York, United States Tennessee, United States Texas, United States
Prior IO Allowed	Yes
CRC-directed	Yes
Status	Completed
Drugs	
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT03990233
Title	A Trial of BI 765063 Monotherapy and in Combination With BI 754091 in Patients With Advanced Solid Tumours
Phase	Phase 1
Date Added	2019-06-18
Location	Belgium France
Prior IO Allowed	Yes
CRC-directed	No
Status	Completed
Drugs	BI 754091, BI 765063
Tags	MSS/ MMRp
NCT ID	NCT03412877
Title	Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
Phase	Phase 2
Date Added	2018-01-29
Location	Maryland, United States
Prior IO Allowed	Yes
CRC-directed	No
Status	Recruiting
Drugs	Aldesleukin, Cyclophosphamide, Fludarabine, Individual Patient TCR-Transduced PBL, Pembrolizumab (Keytruda)
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT03530397
Title	A Study to Evaluate MEDI5752 in Subjects With Advanced Solid Tumors
Phase	Phase 1
Date Added	2018-05-21
Location	Michigan, United States New York, United States North Carolina, United States Rhode Island, United States Tennessee, United States Virginia, United States Australia France Italy Korea, Republic of Netherlands Portugal Spain Taiwan

Prior IO Allowed	Yes
CRC-directed	No
Status	Active, not recruiting
Drugs	Carboplatin, MEDI5752, Pembrolizumab, Pemetrexed, Alimta, Imfinzi, Keytruda, Paraplatin
Tags	MSI-H/ MMRd, MSS/ MMRp
<hr/>	
NCT ID	NCT03985891
Title	The Efficacy of JS001 Combined With Chemotherapy in Patients With Locally Advanced Colon Cancer
Phase	Phase 1/Phase 2
Date Added	2019-06-14
Location	China
Prior IO Allowed	Yes
CRC-directed	Yes
Status	Recruiting
Drugs	Anti-PD-1 Monoclonal Antibody JS001, Chemotherapy
Tags	MSI-H/ MMRd, MSS/ MMRp
<hr/>	
NCT ID	NCT03783403
Title	A Study of CC-95251, a Monoclonal Antibody Directed Against SIRP?, in Participants With Advanced Solid and Hematologic Cancers
Phase	Phase 1
Date Added	2018-12-21
Location	Alabama, United States Arizona, United States California, United States Colorado, United States Missouri, United States New York, United States North Carolina, United States Oklahoma, United States Oregon, United States Pennsylvania, United States Tennessee, United States Texas, United States Australia Canada France Italy Korea, Republic of Spain United Kingdom
Prior IO Allowed	Yes
CRC-directed	No
Status	Active, not recruiting
Drugs	CC-95251, cetuximab, Rituximab
Tags	MSS/ MMRp
<hr/>	
NCT ID	NCT01061515
Title	Biweekly Intraperitoneal Oxaliplatin With Systemic Capecitabine and Bevacizumab for Patients With Peritoneal Carcinomatosis From Appendiceal or Colorectal Cancer
Phase	Phase 1
Date Added	2010-02-03
Location	Missouri, United States
Prior IO Allowed	Yes
CRC-directed	Yes

Status	Active, not recruiting
Drugs	Bevacizumab, capecitabine, Intraperitoneal Oxaliplatin, Avastin, Eloxatin, Xeloda
Tags	MSS/ MMRp